Microsoft, Verizon Communications And 3 Stocks To Watch Heading Into Tuesday
With US stock futures trading mostly flat this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
Markets Turn More Bullish Ahead Of Earnings
The CNN Money Fear and Greed index showed improvement in overall market sentiment among US investors.
US stocks closed higher ahead of a busy week of earnings. Markets are expecting the US Federal Reserve to increase rates by 25 basis points at its upcoming meeting.
Tesla, Microsoft, IBM, Intel, TI Among Companies Reporting This Week: Can Netflix’s Optimism Spill Over To Rest Of Tech Space?
Netflix, Inc. (NASDAQ: NFLX) shares jumped nearly 8.5% on Friday before settling at their highest level since April 19, 2022, when shares plunged after the company reported its first loss in net paid subscriber adds in a decade.
SVB Leerink Maintains Outperform on Johnson & Johnson, Lowers Price Target to $186
SVB Leerink analyst David Risinger maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and lowers the price target from $194 to $186.
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In Q1 2023
In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ:VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major Depressive
Johnson & Johnson Earnings Conference Call Is Coming Up, Here’s What You Need To Know
Johnson & Johnson (NYSE:JNJ) will host a conference call at 08:30 AM ET on January 24, 2023, to…
Johnson & Johnson’s HIV Vaccine Regimen Does Not Prevent Infection, Phase 3 Study Shows
The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced the results of an independent, scheduled data review of the Phase 3 Mosaico study of the investigational HIV vaccine regimen.
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand.